Eli Lilly jumps into the tech-dominated $1 trillion club
, propelled by sales of its blockbuster weight-loss drugs, joined tech giants including and as it hit a $1 trillion valuation on Friday. The American pharmaceutical giant’s market cap eclipsed $1 tr...
LifeMD reports earnings miss, weak guidance amid “fierce competition” in GLP-1 market
plunged in early trading Tuesday after it reported earnings results on Monday that missed Wall Street estimates, which it attributed in part to “fierce competition from low-price compounded GLP-1 prov...
Novo drops price for introductory GLP-1 doses, undercutting its competitors
slashed the cash-pay price for starting doses of its diabetes and weight-loss shots, Ozempic and Wegovy, in a bold move to boost sales after it’s lost ground in the GLP-1 market to Eli Lilly and compo...
Mangoceuticals’ partnership with Eli Lilly and Novo Nordisk? News to them.
, a microcap telehealth startup, announced that it’s partnering with and to sell their blockbuster weight-loss drugs. It appears nobody told the pharmaceutical giants about the deal. The company, wh...
White House unveils deal with Novo, Lilly on weight-loss drugs
The White House announced that it has reached a deal with and to lower the price of their some of their blockbuster GLP-1 drugs starting next year in exchange for Medicare and Medicaid covering th...
Moderna jumps after reporting much smaller Q3 loss than feared; sales also beat estimates
rose in premarket trading after it reported third-quarter results that crushed Wall Street estimates. The company reported a loss per share of $0.51, significantly less than the $2.21 loss per share a...
Blockbuster drug sales power Big Pharma’s Q3 earnings as tariff fears fade
Drug sales, driven by blockbuster weight-loss and diabetes drugs, continued to impress Wall Street this earnings season as the pharmaceutical industry’s tariff fears start to fade. Most major drugmake...
Novo Nordisk cuts outlook again amid obesity drug slowdown and Pfizer bidding war
reported quarterly earnings results Wednesday that missed Wall Street estimates, as the company fights a bidding war that could determine its future in the obesity drug market. The Danish pharmaceutic...
Pfizer reports earnings beat and boosts guidance as Metsera bid-off heats up
rose in early trading after it reported earnings results on Tuesday that beat Wall Street estimates as the company is embroiled in the middle of a bid-off for obesity biotech Metsera. The pharmaceutic...
Kimberly-Clark to buy Tylenol maker Kenvue, target of Trump’s autism attacks, in a deal worth $48.7 billion
Giant American drugmaker Kimberly-Clark said it is set to buy Kenvue, the maker of Tylenol whose stock has been pummeled by allegations from the Trump administration that its signature pain reliever c...
Gene-editing stocks rally on Bloomberg report that FDA plans to fast-track approval process
Shares of biotechs working with gene-editing treatments rose after the industry’s top regulator told Bloomberg News that the Food and Drug Administration plans to publish a paper in early November out...
AbbVie earnings beat estimates but sag on decline in oncology and aesthetics biz
slipped after it reported earnings results that beat Wall Street estimates, but also showed a slowdown in its oncology and aesthetics business. The company reported adjusted quarterly earnings per sha...
Moderna soars after STAT reports “a buyout or a large partnership” are on the table
rose nearly 15% on Thursday after STAT reported that the company has flirted with the idea of tying up with a larger drugmaker. The Covid vaccine maker has talked to at least one large drugmaker on a ...
Eli Lilly rises after earnings, sales blow past Wall Street’s expectations
rose after it reported earnings and revenue that beat Wall Street expectations, driven by better-than-expected sales of its blockbuster diabetes shot Mounjaro. The company reported adjusted earnings p...
The US obesity rate keeps declining, but diabetes cases have hit a new high
Weight-loss drugs like Ozempic have long had a significant impact on pharma companies’ financials . Now, we’re starting to see GLP-1s affecting America’s health statistics in real time. On Tuesday, Ga...
Hims to begin selling GLP-1 microdosing treatments
said Wednesday that it will begin offering GLP-1 “microdosing treatments,” doubling down on selling copycat versions of the blockbuster weight-loss drugs made by . “Microdosing” GLP-1s generally refe...
Eli Lilly strikes deal with Walmart to distribute cash-pay Zepbound vials
announced that it’s partnering with to distribute cheaper, cash-pay options for its blockbuster weight-loss shot Zepbound. Zepbound vials will be available at Walmarts nationwide by mid-November, the...
Lilly partners with Nvidia to build supercomputer for drug R&D
is partnering with to build “the most powerful supercomputer owned and operated by a pharmaceutical company” to help discover new medicines. The drugmaker announced the deal on Tuesday, following a s...
Intellia tanks as it pauses late-stage CRISPR gene-editing trials after one patient was hospitalized
dropped sharply on Monday after it announced that it’s pausing two late-stage CRISPR gene-editing trials because one patient was hospitalized with liver damage. Intellia had also disclosed in May that...
West Pharmaceutical jumps on continued GLP-1 demand
, which manufactures injectable pharmaceutical packaging, rose more than 14% in early trading after it reported earnings results that beat Wall Street estimates, bolstered by sales of components that ...